BG Medicine, Inc. (BGMD) Stock Price & Analysis

BG Medicine, Inc. (BGMD) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 450 shares. Market capitalization is $1,137, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 24, 2026 at 02:19 UTC.

Also available as compact Markdown for AI agents: nexqual.com/BGMD.md

Key facts (BGMD)

Analysts (BGMD)

Consensus None.

Total return (dividends reinvested) (BGMD)

1Y (from 2025-10-24)5Y (from 2021-10-25)
Total return+0.0%+0.0%
S&P 500 (SPY)+13.4%+76.9%
Per year+0.0%+0.0%
Volatility (annualized)0.0%77.2%
Max drawdown+0.0% (→)-75.0% (Dec 2022→Jan 2023)

BGMD analyst estimates and revisions

PeriodEPS estimate90 days agoChangeRevenue estimateAnalysts
Current quarter———$0—
Next quarter (ends Jun 2015)———$0—
Current fiscal year (ends Dec 2015)———$0—
Next fiscal year———$0—

Key Statistics (as of October 24, 2026 at 02:19 UTC)

PriceUSD 0
Change▲ 0.00% (up)
Previous CloseUSD 0
OpenUSD 0
Day RangeUSD 0 – 0
52-Week RangeUSD 0 – 0
Volume450 shares
Market Cap$1,137
ExchangePNK

Technical Analysis (BGMD)

Nexqual's technical model rates BGMD "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 24, 2026 at 02:19 UTC.

Overall SignalSTRONG SELL
RSI (14)100 (overbought)
vs SMA50Below (USD 0)
MACD0 (negative)

Analyst Ratings (BGMD)

Wall Street analysts rate BGMD "None", per Nexqual as of October 24, 2026 at 02:19 UTC.

Consensus RatingNone

Earnings (BGMD)

Recent Earnings History

QuarterActual vs Estimate
2014-12-31USD -0.16 vs est -0.2 ▲ beat
2014-09-30USD -0.28 vs est -0.24 ▼ miss
2014-06-30USD -0.24 vs est -0.24 ▲ beat
2014-03-31USD -0.32 vs est -0.32 ▲ beat

Source: Nexqual, October 24, 2026 at 02:19 UTC.

Financials & Fundamentals (BGMD)

Total Revenue$1.57M
Revenue Growth (latest quarter, YoY)-47.70%
Gross Margin+67.75%
Operating Margin-290.69%
Profit Margin+0.00%
ROE-902.64%
Current Ratio1.65
Total Cash$1.52M
Total Debt$0

Source: Nexqual, October 24, 2026 at 02:19 UTC.

Financial Health Score (BGMD)

Nexqual rates BG Medicine, Inc.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 02:19 UTC.

GrowthCritical — Revenue -32% YoY (annual), sharp decline
ProfitabilityCritical — Heavily loss-making — early-stage company
Balance SheetMixed — $2M cash, no debt
Cash FlowWeak — Operating cash flow -$4M (TTM)
EfficiencyCritical — ROE -903%, ROA -75.9%

Ownership (BGMD)

Insider Ownership+0.00%
Institutional Ownership+0.00%
Shares Outstanding11.37M
Float8.31M
Short % of Float+12.45%

Source: Nexqual, October 24, 2026 at 02:19 UTC.

Leadership (BGMD)

BG Medicine, Inc. is led by Stephen P. Hall, CFO, Executive VP & Treasurer, per Nexqual as of October 24, 2026 at 02:19 UTC.

CFO, Executive VP & TreasurerStephen P. Hall

Peers & Related Stocks

SymbolNamePriceChange
KMTSKestra Medical Technologies, LtUSD 28.76▲ 1.55%
XRAYDENTSPLY SIRONA Inc.USD 9.43▼ 0.74%
LMATLeMaitre Vascular, Inc.USD 84.45▼ 1.03%
ATRCAtriCure, Inc.USD 58.97▼ 0.56%
WRBYWarby Parker Inc.USD 25.91▲ 0.93%
PLSEPulse Biosciences, IncUSD 53.02▲ 0.65%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 02:19 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt